Examining the frequency of stimulant misuse among patients with primary disorders of hypersomnolence: A retrospective cohort study

Journal of Clinical Sleep Medicine

Volumn 12, Issue 5, 2016, Pages 659-662

  Mantyh, William G ^a   Auger, R Robert ^a   Morgenthaler, Timothy I ^a   Silber, Michael H ^a   Moore, Wendy R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Narcolepsy; Primary hypersomnolence; Stimulant misuse

Indexed keywords

AMPHETAMINE DERIVATIVE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL;

ADULT; ARTICLE; CATAPLEXY; COHORT ANALYSIS; DEPRESSION; DRUG MISUSE; FEMALE; FOLLOW UP; HUMAN; HYPERSOMNIA; IDIOPATHIC HYPERSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NARCOLEPSY; NURSING STAFF; PRESCRIPTION; RETROSPECTIVE STUDY; SLEEP; SLEEP DISORDER ASSESSMENT; SOMNOLENCE; SUBSTANCE ABUSE; TREATMENT DURATION; AMPHETAMINE DEPENDENCE; COMORBIDITY; STATISTICS AND NUMERICAL DATA;

ADULT; AMPHETAMINE-RELATED DISORDERS; AMPHETAMINES; COHORT STUDIES; COMORBIDITY; DISORDERS OF EXCESSIVE SOMNOLENCE; DRUG MISUSE; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES;

EID: 84969218894     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.5788     Document Type: Article

References (34)

1. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30:1705-11.
2. Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF. Treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30:1712-27.
3. Dasgupta N. StreetRx. Accessed 2015. Available from: http://streetrx.com/.
4. United States Drug Enforcement Administration. Drug Fact Sheets. Accessed 2015. Available from: http://www.dea.gov/druginfo/factsheets.shtml.
5. Jaffe SL. Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD. J Am Acad Child Adolesc Psychiatry 1991;30:773-5.
6. Parran TV Jr., Jasinski DR. Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Arch Intern Med 1991;151:781-3.
7. Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzwelder HS. The misuse and diversion of prescribed ADHD medications by college students. J Atten Disord 2009;13:144-53.
8. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000;14:53-60.
9. O'Brien CP. Drug addiction and drug abuse. In: Gilman AG, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, eds. Goodman and Gilman's The pharmacological basis of therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996:557-77.
10. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995;52:456-63.
11. Volkow ND, Wang GJ, Fowler JS, et al. Association of methylphenidateinduced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry 1999;156:19-26.
12. Kaye S, Darke S. The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care? Addiction 2012;107:467-77.
13. McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse 2004;39:1095-116.
14. Musser CJ, Ahmann PA, Theye FW, Mundt P, Broste SK, Mueller-Rizner N. Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. J Dev Behav Pediatr 1998;19:187-92.
15. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47:21-31.
16. Novak SP, Kroutil LA, Williams RL, Van Brunt DL. The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy 2007;2:32.
17. Auger RR, Goodman SH, Silber MH, Krahn LE, Pankratz VS, Slocumb NL. Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study. Sleep 2005;28:667-72.
18. Dupont RL, Coleman JJ, Bucher RH, Wilford BB. Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Am J Addict 2008;17:167-71.
19. American Academy of Sleep Medicine. The international classification of sleep disorders: diagnostic and coding manual, 2nd ed. Westchester, IL: American Academy of Sleep Medicine, 2005.
20. Thorpy M, Chesson A, Ferber R, et al. Practice parameters for the use of stimulants in the treatment of narcolepsy. Standards of Practice Committee of the American Sleep Disorders Association. Sleep 1994;17:348-51.
21. Desantis A, Noar SM, Webb EM. Nonmedical ADHD stimulant use in fraternities. J Stud Alcohol Drugs 2009;70:952-4.
22. Franke AG, Bonertz C, Christmann M, et al. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 2011;44:60-6.
23. Jeffers A, Benotsch EG, Koester S. Misuse of prescription stimulants for weight loss, psychosocial variables, and eating disordered behaviors. Appetite 2013;65:8-13.
24. McCabe SE, West BT. Medical and nonmedical use of prescription stimulants: results from a national multicohort study. J Am Acad Child Adolesc Psychiatry 2013;52:1272-80.
25. American Academy of Sleep Medicine. The international classification of sleep disorders, 3rd ed. Darien, IL: American Academy of Sleep Medicine, 2014.
26. Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009;301:1148-54.
27. Nguyen TL, Tian YH, You IJ, Lee SY, Jang CG. Modafinil-induced conditioned place preference via dopaminergic system in mice. Synapse 2011;65:733-41.
28. Deroche-Gamonet V, Darnaudery M, Bruins-Slot L, Piat F, Le Moal M, Piazza PV. Study of the addictive potential of modafinil in naive and cocaineexperienced rats. Psychopharmacology (Berl) 2002;161:387-95.
29. Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance-A review of abuse liability issues. Ann Clin Psychiatry 2004;16:101-9.
30. Aston-Jones G, Smith RJ, Sartor GC, et al. Lateral hypothalamic orexin/ hypocretin neurons: a role in reward-seeking and addiction. Brain Res 2010;1314:74-90.
31. Borgland SL, Ungless MA, Bonci A. Convergent actions of orexin/hypocretin and CRF on dopamine neurons: emerging players in addiction. Brain Res 2010;1314:139-44.
32. Boutrel B, de Lecea L. Addiction and arousal: the hypocretin connection. Physiol Behav 2008;93:947-51.
33. Pilkinton MC. Nonmedical use of prescription stimulants: age, race, gender, and educational attainment patterns. J Hum Behav Soc Environ 2012;22:409-20.
34. Sweeney CT, Sembower MA, Ertischek MD, Shiffman S, Schnoll SH. Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse. J Addict Dis 2013;32:1-10.